Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Price and Financial Metrics

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): $146.33

1.41 (+0.97%)

POWR Rating

Component Grades













Add JAZZ to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where JAZZ ranks best; there it ranks ahead of 97.6% of US stocks.
  • The strongest trend for JAZZ is in Stability, which has been heading up over the past 177 days.
  • JAZZ ranks lowest in Momentum; there it ranks in the 32nd percentile.

JAZZ Stock Summary

  • JAZZ PHARMACEUTICALS PLC's market capitalization of $8,947,464,430 is ahead of 83.31% of US-listed equities.
  • Over the past twelve months, JAZZ has reported earnings growth of -157.18%, putting it ahead of merely 10.01% of US stocks in our set.
  • The volatility of JAZZ PHARMACEUTICALS PLC's share price is greater than that of just 8.82% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to JAZZ PHARMACEUTICALS PLC, a group of peers worth examining would be REKR, GAN, INPX, EGLX, and TRUE.
  • JAZZ's SEC filings can be seen here. And to visit JAZZ PHARMACEUTICALS PLC's official web site, go to www.jazzpharma.com.

JAZZ Valuation Summary

  • In comparison to the median Healthcare stock, JAZZ's price/sales ratio is 48.94% lower, now standing at 2.4.
  • Over the past 192 months, JAZZ's price/sales ratio has gone down 6.5.

Below are key valuation metrics over time for JAZZ.

Stock Date P/S P/B P/E EV/EBIT
JAZZ 2023-03-24 2.4 2.9 -39.9 -146.7
JAZZ 2023-03-23 2.4 2.8 -38.9 -144.2
JAZZ 2023-03-22 2.4 2.8 -39.1 -144.9
JAZZ 2023-03-21 2.4 2.9 -39.5 -145.7
JAZZ 2023-03-20 2.4 2.8 -39.0 -144.5
JAZZ 2023-03-17 2.3 2.8 -38.2 -142.6

JAZZ Growth Metrics

    Its 2 year revenue growth rate is now at 50.82%.
  • The 4 year net income to common stockholders growth rate now stands at -31.5%.
  • The 3 year net cashflow from operations growth rate now stands at -16.25%.
JAZZ's revenue has moved up $1,422,221,000 over the prior 33 months.

The table below shows JAZZ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3,583.982 1,107.761 -18.687
2022-06-30 3,481.445 963.83 -51.872
2022-03-31 3,300.378 702.489 -449.853
2021-12-31 3,094.238 778.507 -329.668
2021-09-30 2,863.024 787.023 -160.903
2021-06-30 2,625.797 770.852 40.164

JAZZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JAZZ has a Quality Grade of C, ranking ahead of 58.49% of graded US stocks.
  • JAZZ's asset turnover comes in at 0.32 -- ranking 143rd of 680 Pharmaceutical Products stocks.
  • REGN, AGLE, and NTLA are the stocks whose asset turnover ratios are most correlated with JAZZ.

The table below shows JAZZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.320 0.904 0.095
2021-03-31 0.380 0.934 0.196
2020-12-31 0.392 0.937 0.103
2020-09-30 0.395 0.941 0.076
2020-06-30 0.397 0.944 0.064
2020-03-31 0.402 0.944 0.073

JAZZ Price Target

For more insight on analysts targets of JAZZ, see our JAZZ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $207.82 Average Broker Recommendation 1.37 (Strong Buy)

JAZZ Stock Price Chart Interactive Chart >

Price chart for JAZZ

JAZZ Price/Volume Stats

Current price $146.33 52-week high $169.98
Prev. close $144.92 52-week low $125.36
Day low $144.43 Volume 505,100
Day high $146.96 Avg. volume 530,129
50-day MA $145.89 Dividend yield N/A
200-day MA $148.97 Market Cap 9.27B

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) Company Bio

Jazz Pharmaceuticals is an international biopharmaceutical company with a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. The company was founded in 2003 and is based in Dublin, Ireland.

JAZZ Latest News Stream

Event/Time News Detail
Loading, please wait...

JAZZ Latest Social Stream

Loading social stream, please wait...

View Full JAZZ Social Stream

Latest JAZZ News From Around the Web

Below are the latest news stories about JAZZ PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.

Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 31, 2023

The 3 Best Growth Stocks to Buy in the Biotech Sector

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Ian Cooper on InvestorPlace | March 30, 2023

Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients th

Yahoo | March 30, 2023

My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years

A few years ago, the cannabis industry attracted much interest from investors following significant regulatory changes in Canada and anticipated progress elsewhere in developed countries. Let's first review how Jazz Pharmaceuticals entered the cannabis market. In May 2021, the company acquired GW Pharmaceuticals, a drugmaker focusing on developing cannabidiol (CBD)-based medicines.

Yahoo | March 21, 2023

Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca® (lurbinectedin), zanidatamab and JZP898.

Yahoo | March 15, 2023

Read More 'JAZZ' Stories Here

JAZZ Price Returns

1-mo 1.38%
3-mo -8.15%
6-mo 8.03%
1-year -7.91%
3-year 52.94%
5-year 0.00%
YTD -8.15%
2022 25.05%
2021 -22.81%
2020 10.56%
2019 20.43%
2018 -7.94%

Continue Researching JAZZ

Here are a few links from around the web to help you further your research on Jazz Pharmaceuticals plc's stock as an investment opportunity:

Jazz Pharmaceuticals plc (JAZZ) Stock Price | Nasdaq
Jazz Pharmaceuticals plc (JAZZ) Stock Quote, History and News - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8245 seconds.